Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00162864 · ClinicalTrials.gov registry record · Phase 3

A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease

A Phase 3 study, sponsored by Kaiser Permanente.

Completed
Registry status
Phase 3
Development phase
200
Enrollment target

NCT00162864 is a Phase 3 study that has completed, run by Kaiser Permanente. The registered enrollment target is 200 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00162864, a Phase 3 study, has completed, sponsored by Kaiser Permanente.

COMPLETED
Registry status
Phase 3
Development phase
200 participants
Enrollment target

Study Summary

This randomized, double-blind, placebo-controlled trial assessed the efficacy of montelukast in the treatment of adults ≥50 years of age with persistent asthma and/or COPD. Primary outcomes included forced expiratory volume in one-second (FEV1) and daytime asthma symptoms scores. Nocturnal symptoms, asthma control, health-related quality of life, peak flow measurements, and health care utilization were also assessed as secondary outcomes. Participants were recruited from the Kaiser Permanente Northwest member population. One hundred forty-nine subjects were randomized to treatment with montelukast (10 mg per day) or placebo, and were followed for a six-week period. No differences in lung function measures, health-related quality of life, health care utilization, and asthma symptom scores were observed; however, the montelukast group had slightly improved asthma control scores compared to the placebo group.

Interventions

  • DRUG montelukast sodium

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 1999-12
Est. Completion 2002-04
Phase Phase 3

Sponsor

Kaiser Permanente

294 total trials

What the Registry Record Tells You About NCT00162864

The ClinicalTrials.gov registry entry for NCT00162864 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which montelukast sodium is the first listed.

NCT00162864 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00162864 about?

NCT00162864 is a clinical study titled "A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease". This randomized, double-blind, placebo-controlled trial assessed the efficacy of montelukast in the treatment of adults ≥50 years of age with persistent asthma and/or COPD. Primary outcomes included forced expiratory volume in one-second (FEV1) and daytime asthma symptoms scores. Nocturnal symptoms,...

What is the current status of trial NCT00162864?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 1999-12. Estimated completion is 2002-04.

What interventions are being tested in trial NCT00162864?

The interventions under investigation include: montelukast sodium (DRUG).

Who is sponsoring clinical trial NCT00162864?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.